



ELSEVIER

Contents lists available at ScienceDirect

Parkinsonism and Related Disorders

journal homepage: www.elsevier.com/locate/parkreldis

Correspondence

Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study



ARTICLE INFO

Keywords:

Substantia nigra pars compacta
Subthalamic stimulation
Low frequency

We have read with interest the letter sent by Dr. Weiss et al. We appreciate very much their comment especially considering that his group was the first one publishing the possible beneficial effects of combined subthalamic and nigral stimulation to improve gait problems associated to Parkinson's disease [1]. In our study, indeed, we studied gait problems resistant to levodopa therapy or to any other pharmacological treatment.

We agree that there are no comparative data between low- and high-frequency SNr stimulation (neither SNr alone nor combined with STN) at the present moment. In fact the main reason for stimulating the substantia nigra pars reticulata at low frequency (63 Hz) in our study was that we believed that at this rate of stimulation the probability of inducing side effects would be lower considering the number of structures surrounding the nigra (oculomotor, sensitive, etc.) In addition we also tested this low frequency setting based on the previous published works showing beneficial effects on parkinsonian gait problems when stimulating at frequencies ranging from 60 to 80 Hz at the most ventral part of the subthalamic nucleus [2–6].

In fact, although in our study the lower stimulation contacts were located at substantia nigra pars reticulata we cannot rule out the possibility of certain effect at the ventral subthalamus. In most of patients we did not use the lower contact because of side effects, and consequently the volume of tissue activated could perfectly influence the ventral subthalamic nucleus. We are now thinking about the possibility of initiating a new study targeting the subthalamic nucleus using high frequency stimulation at the dorsal part of the nucleus and low frequency stimulation at the ventral areas.

We definitely agree with Dr. Weiss et al., that more detailed basic research and clinical work is needed to ascertain the role of nigral stimulation in the treatment of parkinsonian gait disorders.

References

- [1] D. Weiss, M. Walach, C. Meisner, M. Fritz, M. Scholten, S. Breit, C. Plewnia, B. Bender, A. Gharabaghi, T. Wächter, R. Krüger, Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial, *Brain* 136 (2013) 2098–2108.
- [2] C. Moreau, L. Defebvre, A. Destee, S. Bleuse, F. Clement, J.L. Blatt, P. Krystkowiak, D. Devos, STN-DBS frequency effects on freezing of gait in advanced Parkinson disease, *Neurology* 71 (2008) 80–84.
- [3] A. Fasano, A.M. Lozano, The FM/AM world is shaping the future of deep brain stimulation, *Mov. Disord.* 29 (2014) 161–163.
- [4] V. Ricchi, M. Zibetti, S. Angrisano, A. Merola, N. Arduino, C.A. Artusi, M. Rizzone, L. Lopiano, M. Lanotte, Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study, *Brain Stimul.* 5 (2012) 388–392.
- [5] C. Sidiropoulos, R. Walsh, C. Meaney, Y.Y. Poon, M. Fallis, E. Moro, Low-frequency subthalamic nucleus deep brain stimulation for axial symptoms in advanced Parkinson's disease, *J. Neurol.* 260 (2013) 2306–2311.
- [6] T. Xie, M. Padmanaban, L. Bloom, E. MacCracken, B. Bertacchi, A. Dachman, P. Warnke, Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review, *Transl. Neurodegener.* 6 (2017) 13.

Francesc Valldeoriola
Institut de Neurociències, Hospital Clínic de Barcelona, University of
Barcelona, Spain

E-mail address: fvalle@clinic.uib.es.

<https://doi.org/10.1016/j.parkreldis.2018.12.009>

Received 21 November 2018; Accepted 10 December 2018

1353-8020/ © 2018 Elsevier Ltd. All rights reserved.